ICICI Prudential Asset Management Co Ltd trimmed its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 66.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,254 shares of the medical instruments supplier’s stock after selling 10,364 shares during the period. ICICI Prudential Asset Management Co Ltd’s holdings in West Pharmaceutical Services were worth $1,948,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently bought and sold shares of WST. BlackRock Inc. acquired a new stake in West Pharmaceutical Services during the 2nd quarter worth about $2,387,990,000. State Street Corp increased its holdings in shares of West Pharmaceutical Services by 1.7% in the 2nd quarter. State Street Corp now owns 3,348,698 shares of the medical instruments supplier’s stock valued at $1,202,183,000 after purchasing an additional 54,920 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at about $733,733,000. Generation Investment Management LLP acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at about $728,168,000. Finally, Findlay Park Partners LLP purchased a new stake in shares of West Pharmaceutical Services in the second quarter worth approximately $214,196,000. 93.90% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
WST has been the subject of several research reports. Barclays raised their price target on shares of West Pharmaceutical Services from $440.00 to $500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. Citigroup upped their price objective on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the company a “buy” rating in a research note on Friday, October 30th. UBS Group increased their target price on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Finally, Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and an average target price of $424.67.
Read Our Latest Stock Report on West Pharmaceutical Services
West Pharmaceutical Services Price Performance
WST opened at $416.34 on Monday. The stock has a market cap of $29.00 billion, a price-to-earnings ratio of 46.73, a PEG ratio of 2.53 and a beta of 1.13. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $438.27. The company has a current ratio of 2.82, a quick ratio of 2.10 and a debt-to-equity ratio of 0.07. The stock has a fifty day moving average price of $380.32 and a 200 day moving average price of $320.84.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The firm had revenue of $874.50 million for the quarter, compared to the consensus estimate of $827.12 million. During the same quarter in the previous year, the company posted $1.96 earnings per share. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. Analysts forecast that West Pharmaceutical Services, Inc. will post 9.45 EPS for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th will be issued a dividend of $0.26 per share. The ex-dividend date is Tuesday, November 10th. This represents a $1.04 annualized dividend and a dividend yield of 0.2%. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s dividend payout ratio is presently 11.67%.
Insider Activity at West Pharmaceutical Services
In other West Pharmaceutical Services news, VP Annette Favorite sold 2,524 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total value of $921,260.00. Following the completion of the sale, the vice president directly owned 21,818 shares of the company’s stock, valued at $7,963,570. The trade was a 10.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 15,659 shares of company stock valued at $5,443,749. Insiders own 0.60% of the company’s stock.
About West Pharmaceutical Services
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Read More
- Five stocks we like better than West Pharmaceutical Services
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
